Lineage, Inc. Common Stock (LINE)vsSabra Healthcare REIT Inc (SBRA)
LINE
Lineage, Inc. Common Stock
$35.99
-1.64%
REAL ESTATE · Cap: $8.93B
SBRA
Sabra Healthcare REIT Inc
$20.35
-0.78%
REAL ESTATE · Cap: $5.13B
Smart Verdict
WallStSmart Research — data-driven comparison
Lineage, Inc. Common Stock generates 590% more annual revenue ($5.36B vs $775.76M). SBRA leads profitability with a 20.1% profit margin vs -1.9%. SBRA earns a higher WallStSmart Score of 57/100 (C).
LINE
Hold36
out of 100
Grade: F
SBRA
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+75.9%
Fair Value
$161.49
Current Price
$35.99
$125.50 discount
Margin of Safety
+84.7%
Fair Value
$127.86
Current Price
$20.35
$107.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 20 of every $100 in revenue as profit
Reasonable price relative to book value
Strong operational efficiency at 23.7%
15.8% revenue growth
Areas to Watch
0.0% earnings growth
ROE of -1.2% — below average capital efficiency
Revenue declined 0.2%
Distress zone — elevated risk
Premium valuation, high expectations priced in
ROE of 5.6% — below average capital efficiency
Expensive relative to growth rate
Earnings declined 44.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : SBRA
The strongest argument for SBRA centers on Profit Margin, Price/Book, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 23.7%. Revenue growth of 15.8% demonstrates continued momentum.
Bear Case : LINE
The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.
Bear Case : SBRA
The primary concerns for SBRA are P/E Ratio, Return on Equity, PEG Ratio.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while SBRA is a growth play — different risk/reward profiles.
SBRA is growing revenue faster at 15.8% — sustainability is the question.
SBRA generates stronger free cash flow (87M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SBRA scores higher overall (57/100 vs 36/100), backed by strong 20.1% margins and 15.8% revenue growth. LINE offers better value entry with a 75.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm focused on regenerative medicine, specifically developing cutting-edge cell therapy solutions for treating debilitating conditions, including ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust network of strategic collaborations, Lineage is poised to transform patient care through innovative therapeutic interventions. The company's commitment to advancing its diverse product pipeline and expediting clinical research positions it as an attractive investment opportunity for institutional investors seeking to engage in the forefront of healthcare advancements.
Visit Website →Sabra Healthcare REIT Inc
REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA
As of September 30, 2020, Sabra's investment portfolio included 425 real estate properties held for investment (consisting of (i) 287 skilled nursing / transitional care facilities, (ii) 64 senior housing communities (?
Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?